Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02542293 · ClinicalTrials.gov registry record · Phase 3

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

A Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
953
Enrollment target
20
Study locations

NCT02542293: Active Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca.

NCT02542293 is a Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 953 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02542293, a Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
953 participants
Enrollment target
20
Study locations

Study Summary

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.

Primary Outcome

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Conditions Studied

Non-Small-Cell Lung Carcinoma NSCLC

Interventions

  • DRUG Gemcitabine + cisplatin
  • DRUG Gemcitabine + carboplatin
  • DRUG Paclitaxel + carboplatin
  • DRUG Pemetrexed + cisplatin
  • BIOLOGICAL Durvalumab +Tremelimumab

Study Locations (20)

Other

  • Research Site - Berazategui
  • Research Site - CABA
  • Research Site - Ciudad de Buenos Aires
  • Research Site - Córdoba
  • Research Site - La Rioja

New York

  • Research Site - East Setauket
  • Research Site - Fresh Meadows
  • Research Site - Poughkeepsie
  • Research Site - Stony Brook

California

  • Research Site - Anaheim
  • Research Site - San Diego
  • Research Site - Santa Rosa

Ohio

  • Research Site - Canton
  • Research Site - Columbus
  • Research Site - Zanesville

Kentucky

  • Research Site - Louisville

New Jersey

  • Research Site - Florham Park

New Mexico

  • Research Site - Albuquerque

Pennsylvania

  • Research Site - Pittsburgh

Trial Details

FieldValue
Enrollment Target 953 participants
Start Date 2015-11-03
Est. Completion 2026-12-31
Phase Phase 3
AstraZeneca

1,285 total trials

What the registry record for NCT02542293 still lists

NCT02542293 is an interventional study that assigns participants to a tested intervention. The registered 953 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% higher).

The record links to 1 condition, with Non-Small-Cell Lung Carcinoma NSCLC appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine + cisplatin is the first listed.

NCT02542293 names 20 study sites across 9 states, led by Other, New York, California.

Frequently Asked Questions

What is clinical trial NCT02542293 about?

NCT02542293 is a clinical study titled "Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)". This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lym...

What is the current status of trial NCT02542293?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 953 participants. The study started on 2015-11-03. Estimated completion is 2026-12-31.

What conditions does trial NCT02542293 study?

This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma NSCLC.

What interventions are being tested in trial NCT02542293?

The interventions under investigation include: Gemcitabine + cisplatin (DRUG), Gemcitabine + carboplatin (DRUG), Paclitaxel + carboplatin (DRUG), Pemetrexed + cisplatin (DRUG), Durvalumab +Tremelimumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02542293?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02542293 being conducted?

This trial has 20 study locations across California, Kentucky, New Jersey, New Mexico, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small-Cell Lung Carcinoma NSCLC

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02542293's enrollment target sits among peer trials

953 333rd of 2000 higher than 1,668 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04375033 · 952 participants · Phase 4

    A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

  • NCT06225596 · 956 participants · Phase 2

    Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

  • NCT03784924 · 950 participants

    EDRN Prostate MRI Biomarker Study

  • NCT04180930 · 950 participants

    An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02542293, the US trial registry maintained by the National Library of Medicine. NCT02542293 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.